[1]滕 远,李莉娟,张连生.髓细胞白血病1抑制剂在多发性骨髓瘤治疗中的研究进展[J].陕西医学杂志,2024,(6):858-861.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.029]
　TENG Yuan,LI Lijuan,ZHANG Liansheng.Research progress of myeloid cell leukemia 1 inhibitors in treatment of multiple myeloma[J].,2024,(6):858-861.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.029]
点击复制

髓细胞白血病1抑制剂在多发性骨髓瘤治疗中的研究进展
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年6期
页码:
858-861
栏目:
综 述
出版日期:
2024-06-05

文章信息/Info

Title:
Research progress of myeloid cell leukemia 1 inhibitors in treatment of multiple myeloma
作者:
滕 远1; 李莉娟1; 2; 张连生1; 2
(1.兰州大学第二临床医学院,甘肃 兰州 730030; 2.兰州大学第二医院血液科,甘肃 兰州 730030)
Author(s):
TENG Yuan; LI Lijuan; ZHANG Liansheng
(Second Clinical Medical College of Lanzhou University,Lanzhou 730030,China)
关键词:
多发性骨髓瘤;  髓细胞白血病1抑制剂;  B细胞淋巴瘤2;  耐药;  自体干细胞移植
Keywords:
Multiple myeloma;  Myeloid cell leukemia 1 inhibitor;  B-cell lymphoma 2;  Drug resistance;  Autologous stem cell transplantation
分类号:
R 733.3
DOI:
DOI:10.3969/j.issn.1000-7377.2024.06.029
文献标志码:
A
摘要:
多发性骨髓瘤(MM)是一种不可治愈的B细胞恶性肿瘤,治疗方案包括化疗和自体干细胞移植。然而,目前药物在控制肿瘤进展和延长MM缓解时间方面作用有限,也并非所有患者都能够接受自体干细胞移植。多结构域B细胞淋巴瘤2(Bcl-2)家族蛋白,特别是髓细胞白血病1(MCL-1)的过度表达在MM的发病机制中起着关键作用。MCL-1过度表达与MM患者耐药和总体不良预后相关。因此,抑制MCL-1蛋白是杀死骨髓瘤细胞的一种治疗策略。在过去的十年中,选择性MCL-1抑制剂的开发取得了显著进展。现对MCL-1抑制剂在MM治疗中的研究进展进行介绍。
Abstract:
Multiple myeloma(MM)is an incurable plasma B-cell malignancy.Treatment options include combination chemotherapy and autologous stem cell transplantation.However,the role of current drugs in controlling tumor progression and prolonging remission time of MM is limited,and not all patients are able to receive autologous stem cell transplantation.The overexpression of Bcl-2 family proteins,particularly myeloid cell leukemia 1(MCL-1), plays a critical role in the pathogenesis of MM.The overexpression of MCL-1 is associated with drug resistance and overall poor prognosis in MM patients.Thus,inhibition of MCL-1 protein is a therapeutic strategy to kill myeloma cells.Over the past decade,significant progress has been made in the development of selective MCL-1 inhibitors.This article reviews the research progress of MCL-1 inhibitors in the treatment of MM.

参考文献/References:

[1] AL-ODAT O,VON-SUSKIL M,CHITREN R,et al.Mcl-1 inhibition:Managing malignancy in multiple myeloma[J].Front Pharmacol,2021,12:699629.
[2] HOLTHOF L C,MUTIS T.Challenges for immunotherapy in multiple myeloma:Bone marrow microenvironment-mediated immune suppression and immune resistance[J].Cancers(Basel),2020,12(4):988.
[3] GOLDSMITH S R,STREETER S,COVUT F.Bispecific antibodies for the treatment of multiple myeloma[J].Curr Hematol Malig Rep,2022,17(6):286-297.
[4] BOUSSI L S,AVIGAN Z M,ROSENBLATT J.Immunotherapy for the treatment of multiple myeloma[J].Front Immunol,2022,13:1027385.
[5] MITTAL P,SINGH S,SINHA R,et al.Myeloid cell leukemia 1(MCL-1):Structural characteristics and application in cancer therapy[J].Int J Biol Macromol,2021,187:999-1018.
[6] SLOMP A,MOESBERGEN L M,GONG J N,et al.Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting[J].Blood Adv,2019,3(24):4202-4214.
[7] OPYDO M,MLYCZYNSKA A,MLYCZYNSKA E,et al.Synergistic action of MCL-1 inhibitor with BCL-2/BCL-XL or MAPK pathway inhibitors enhances acute myeloid leukemia cell apoptosis and differentiation[J].Int J Mol Sci,2023,24(8):7180.
[8] PHILLIPS D C,XIAO Y,LAM L T,et al.Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax(ABT-199)[J].Blood Cancer Journal,2015,5(11):e368-e368.
[9] NAKANO T,GO T,NAKASHIMA N,et al.Overexpression of antiapoptotic MCL-1 predicts worse overall survival of patients with non-small cell lung cancer[J].Anticancer Res,2020,40(2):1007-1014.
[10] ZHANG T,ZOU P,WANG T,et al.Down-regulation of miR-320 associated with cancer progression and cell apoptosis via targeting Mcl-1 in cervical cancer[J].Tumour Biol,2016,37(7):8931-8940.
[11] CAMPBELL K J,MASON S M,WINDER M L,et al.Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function[J].Cell Death Differ,2021,28(9):2589-2600.
[12] LU X,LIANG H,ORVIG C,et al.Peptide and small molecule inhibitors targeting myeloid cell leukemia 1(Mcl-1)as novel antitumor agents[J].Curr Mol Med,2021,21(5):426-439.
[13] GUPTA V A,ACKLEY J,KAUFMAN J L,et al.BCL2 family inhibitors in the biology and treatment of multiple myeloma[J].Blood Lymphat Cancer,2021,11:11-24.
[14] BOLOMSKY A,VOGLER M,KÖSE M C,et al.MCL-1 inhibitors,fast-lane development of a new class of anti-cancer agents[J].J Hematol Oncol,2020,13(1):173.
[15] 靳娟娟,姚玉.MutT同系物1抑制剂对多发性骨髓瘤细胞增殖和凋亡的影响[J].陕西医学杂志,2021,50(8):934-936,948.
[16] 张治业,余醒醒,张璐,等.CD166对多发性骨髓瘤RPMI-8226细胞增殖、凋亡及自噬的影响实验研究[J].陕西医学杂志,2023,52(12):1675-1679.
[17] SLOMP A,PEPERZAK V.Role and regulation of pro-survival BCL-2 proteins in multiple myeloma[J].Front Oncol,2018,8:533.
[18] WEI A H,ROBERTS A W,SPENCER A,et al.Targeting MCL-1 in hematologic malignancies:Rationale and progress[J].Blood Rev,2020,44:100672.
[19] JASROTIA S,GUPTA R,SHARMA A,et al.Cytokine profile in multiple myeloma[J].Cytokine,2020,136:155271.
[20] GU J,HUANG X,ZHANG Y,et al.Cytokine profiles in patients with newly diagnosed multiple myeloma:Survival is associated with IL-6 and IL-17A levels[J].Cytokine,2021,138:155358.
[21] GUPTA V A,MATULIS S M,CONAGE-POUGH J E,et al.Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma[J].Blood,2017,129(14):1969-1979.
[22] ZHANG Y K,WANG H,LENG Y,et al.Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1[J].Biochem Biophys Res Commun,2011,414(1):233-239.
[23] LI X H,HA C T,XIAO M.MicroRNA-30 inhibits antiapoptotic factor Mcl-1 in mouse and human hematopoietic cells after radiation exposure[J].Apoptosis,2016,21(6):708-720.
[24] YANG Y,LI F,SAHA M N,et al.MiR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma[J].Clin Cancer Res,2015,21(10):2399-2411.
[25] WUILLÈME-TOUMI S,ROBILLARD N,GOMEZ P,et al.Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival[J].Leukemia,2005,19(7):1248-1252.
[26] GOMEZ-BOUGIE P,MAIGA S,TESSOULIN B,et al.BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment[J].Blood,2018,132(25):2656-2669.
[27] WANG H,GUO M,WEI H,et al.Targeting MCL-1 in cancer:Current status and perspectives[J].J Hematol Oncol,2021,14(1):67.
[28] LEVERSON J D,ZHANG H,CHEN J,et al.Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263(navitoclax)[J].Cell Death Dis,2015,6(1):e1590.
[29] MUKHERJEE N,STROSNIDER A,VAGHER B,et al.BH3 mimetics induce apoptosis independent of DRP-1 in melanoma[J].Cell Death Dis,2018,9(9):907.
[30] CAENEPEEL S,BROWN S P,BELMONTES B,et al.AMG 176,a selective MCL1 inhibitor,is effective in hematologic cancer models alone and in combination with established therapies[J].Cancer Discov,2018,8(12):1582-1597.
[31] YI X,SARKAR A,KISMALI G,et al.AMG-176,an Mcl-1 antagonist,shows preclinical efficacy in chronic lymphocytic leukemia[J].Clin Cancer Res,2020,26(14):3856-3867.
[32] TRON A E,BELMONTE M A,ADAM A,et al.Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia[J].Nat Commun,2018,9(1):5341.
[33] LIU S,QIAO X,WU S,et al.C-myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia[J].Apoptosis,2022,27(11-12):913-928.
[34] KOTSCHY A,SZLAVIK Z,MURRAY J,et al.The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models[J].Nature,2016,538(7626):477-482.
[35] BRENNAN M S,CHANG C,TAI L,et al.Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use[J].Blood,2018,132(15):1573-1583.
[36] ALGARÍN E M,DÍAZ-TEJEDOR A,MOGOLLN P,et al.Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma[J].Haematologica,2020,105(3):e116-e120.
[37] ALGARÍN E M,QUWAIDER D,CAMPOS-LABORIE F J,et al.Stroma-mediated resistance to S63845 and venetoclax through MCL-1 and BCL-2 expression changes induced by miR-193b-3p and miR-21-5p dysregulation in multiple myeloma[J].Cells,2021,10(3):559.
[38] TAGOUG A,SAFRA I.The impact of panobinostat on cell death in combination with S63845 in multiple myeloma cells[J].Indian J Hematol Blood Transfus,2023,39(2):245-257.
[39] ABULWERDI F,LIAO C,LIU M,et al.A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo[J].Mol Cancer Ther,2014,13(3):565-575.
[40] MALLICK D J,SODERQUIST R S,BATES D,et al.Confounding off-target effects of BH3 mimetics at commonly used concentrations:MIM1,UMI-77,and A-1210477[J].Cell Death Dis,2019,10(3):185.
[41] CAMPBELL K J,DHAYADE S,FERRARI N,et al.MCL-1 is a prognostic indicator and drug target in breast cancer[J].Cell Death Dis,2018,9(2):19.
[42] DENIS C,SOPKOV-DE OLIVEIRA SANTOS J,BUREAU R,et al.Hot-spots of Mcl-1 protein[J].J Med Chem,2020,63(3):928-943.

相似文献/References:

[1]朱清红,李德奎,罗 英.血清尿酸、β2微球蛋白和尿液轻链联合检测〖JZ〗在多发性骨髓瘤早期诊断中的应用[J].陕西医学杂志,2019,(9):1235.
　ZHU Qinghong,LI Dekui,LUO Ying..Combined detection of serum uric acid，β2 microglobulin and urine light chain〖JZ〗in early diagnosis of multiple myeloma[J].,2019,(6):1235.
[2]靳娟娟,姚 玉.MutT同系物1抑制剂对多发性骨髓瘤细胞增殖和凋亡的影响[J].陕西医学杂志,2021,50(8):934.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.008]
　JIN Juanjuan,YAO Yu.Effect of MutT homologue-1 inhibitor on proliferation and apoptosis of multiple myeloma cells[J].,2021,50(6):934.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.008]
[3]杜娟英,薛海鲸.多发性骨髓瘤患者血清微小RNA-424、可溶性晚期糖基化终末产物受体、c-kit受体蛋白检测及临床意义[J].陕西医学杂志,2022,51(12):1585.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.028]
　DU Juanying,XUE Haijing.Detection and clinical significance of serum miR-424,sRAGE and CD117 in patients with multiple myeloma[J].,2022,51(6):1585.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.028]
[4]张治业,余醒醒,张 璐,等.CD166对多发性骨髓瘤RPMI-8226细胞增殖、凋亡及自噬的影响实验研究[J].陕西医学杂志,2023,52(12):1675.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.010]
　ZHANG Zhiye,YU Xingxing,ZHANG Lu,et al.Effects of CD166 on proliferation,apoptosis and autophagy of multiple myeloma RPMI-8226 cells[J].,2023,52(6):1675.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.010]
[5]刘虹伶,王美佳,晏青霞.多发性骨髓瘤患者血清β2-微球蛋白、肿瘤坏死因子-α、乳酸脱氢酶检测及临床意义[J].陕西医学杂志,2024,(3):399.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.024]
　LIU Hongling,WANG Meijia,YAN Qingxia.Detection and clinical significance of serum β2-microglobulin,tumor necrosis factor-α and lactate dehydrogenase in patients with multiple myeloma[J].,2024,(6):399.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.024]
[6]赵思捷,余 航,党珮珠,等.多发性骨髓瘤患者合并心包积液危险因素分析及列线图预测模型构建[J].陕西医学杂志,2024,(12):1635.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.009]
　ZHAO Sijie,YU Hang,DANG Peizhu,et al.Risk factors of multiple myeloma patients with pericardial effusion and construction of nomogram prediction model[J].,2024,(6):1635.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.009]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(82360029)
更新日期/Last Update: 2024-06-05